Back to BAYRYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Blood Loss After a Total Hip Replacement
View Full LandscapeDrug Information
Target Indication
Blood Loss After a Total Hip Replacement
Clinical Trial
NCT02403596Last updated: 9/26/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Developer
Related Pipeline
Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3
Urinary Tract Infection
DabigatranPhase 3
Hematoma
bemdaneprocelPhase 3
Parkinsons Disease (PD)
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3
Acute Coronary Syndrome
Finerenone (Kerendia, BAY94-8862)Phase 3
Chronic Kidney Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts